Final NICE guidance rejects Novartis's higher dose Glivec for GIST
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today published final guidance rejecting Novartis's Glivec (imatinib) in higher doses for patients with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) after standard doses have stopped working. According to the institute, there is not enough evidence to justify use of 600 or 800mg/day.
You may also be interested in...
German HTA: Clinical Cancer Registries Could Hold Key To Better Comparative Data For Benefit Assessments
Better data linkage and data entry systems could transform Germany’s clinical cancer registries into a reliable data source for health technology assessments.
European Health Data Space Talks Falter Over Opt-Out Issue
The pharmaceutical industry has warned co-legislators against any hasty compromises that could impact the competitiveness of EU research.
Germany’s Confidential Pricing Move Could Protect Companies From Potential Trumpian US Reference Pricing
Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.